Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease.

Exp Ther Med · 2013 · PMC3829763 · PMID 24255685

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

difference was apparentP>0.05actually significant

Urine protein levels prior to and following treatment Following treatment, the urine protein level in the spironolactone group had significantly decreased compared with that prior to treatment (P<0.05), whereas no significant difference was apparent in the control group (P>0.05).

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.